dc.contributor.author | Read, A | |
dc.contributor.author | Natrajan, R | |
dc.date.accessioned | 2018-06-15T10:39:02Z | |
dc.date.accessioned | 2019-02-25T09:28:15Z | |
dc.date.issued | 2018-09-01 | |
dc.identifier.citation | Endocrine-related cancer, 2018, 25 (9), pp. R467 - R478 | |
dc.identifier.issn | 1351-0088 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/3080 | |
dc.identifier.eissn | 1479-6821 | |
dc.identifier.doi | 10.1530/erc-18-0068 | |
dc.description.abstract | Breast cancer is known to be a heterogeneous disease driven by a large repertoire of molecular abnormalities, which contribute to its diverse clinical behaviour. Despite the success of targeted therapy approaches for breast cancer patient management, there is still a lack of the molecular understanding of aggressive forms of the disease and clinical management of these patients remains difficult. The advent of high-throughput sequencing technologies has paved the way for a more complete understanding of the molecular make-up of the breast cancer genome. As such, it is becoming apparent that disruption of canonical splicing within breast cancer governs its clinical progression. In this review, we discuss the role of dysregulation of spliceosomal component genes and associated factors in the progression of breast cancer, their role in therapy resistance and the use of quantitative isoform expression as potential prognostic and predictive biomarkers with a particular focus on oestrogen receptor-positive breast cancer. | |
dc.format | Print-Electronic | |
dc.format.extent | R467 - R478 | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | BIOSCIENTIFICA LTD | |
dc.relation.replaces | https://repository.icr.ac.uk/handle/internal/1886 | |
dc.relation.replaces | internal/1886 | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Breast Neoplasms | |
dc.subject | Prognosis | |
dc.subject | Alternative Splicing | |
dc.subject | Drug Resistance, Neoplasm | |
dc.subject | Female | |
dc.subject | Biomarkers | |
dc.title | Splicing dysregulation as a driver of breast cancer. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2018-05-30 | |
rioxxterms.versionofrecord | 10.1530/erc-18-0068 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2018-09 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Endocrine-related cancer | |
pubs.issue | 9 | |
pubs.notes | Not known | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Breast Cancer Research/Functional Genomics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Functional Genomics | |
pubs.publication-status | Published | |
pubs.volume | 25 | |
pubs.embargo.terms | Not known | |
icr.researchteam | Functional Genomics | |
dc.contributor.icrauthor | Read, Abigail | |
dc.contributor.icrauthor | Natrajan, Rachael | |